BMRN Earnings Date: Nov 2, 2026 (Estimated) — BioMarin Pharmaceutical Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is BMRN's next earnings date?
BioMarin Pharmaceutical Inc. (BMRN) is expected to report Q3 2026 earnings on Monday, November 2, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.08 on revenue of $1.02B.
How did BMRN do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), BioMarin Pharmaceutical Inc. posted EPS of $1.20 versus the $0.95 estimate, a beat of 30.4%. Revenue was $990.0M against a $932.0M estimate. The stock's 1-day post-earnings move was +3.8%.
How much does BMRN stock move after earnings?
BMRN beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 2.9% (up or down) in the day after earnings.
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.
🤖 AI Earnings Analysis
BMRN’s 147× P/E leaves little room for error; recent achondroplasia research updates offer pipeline visibility, but the supplied news shows no clear guidance change or earnings surprise.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | 0.95 | 1.20 | +30.43% | $990.0M | ✅ Beat | +3.82% | +11.50% | +8.25% |
| 2026-05-04 | Q1 2026 | 0.89 | 0.76 | -14.61% | $766.2M | ❌ Miss | -4.00% | -5.19% | -1.44% |
| 2026-02-23 | Q4 2025 | 0.36 | 0.46 | +27.78% | $875.0M | ✅ Beat | -0.48% | -5.05% | -14.03% |
| 2025-10-27 | Q3 2025 | 0.51 | 0.12 | -76.47% | $776.1M | ❌ Miss | +1.56% | +0.34% | +6.87% |
| 2025-08-04 | Q2 2025 | 0.93 | 1.44 | +54.84% | $825.4M | ✅ Beat | +2.69% | -5.82% | -2.21% |
| 2025-05-01 | Q1 2025 | 0.71 | 1.13 | +59.15% | $745.1M | ✅ Beat | -1.08% | -4.61% | -9.03% |
| 2025-02-19 | Q4 2024 | 0.74 | 0.92 | +24.32% | $747.0M | ✅ Beat | +4.76% | +4.88% | +9.13% |
| 2024-10-29 | Q3 2024 | 0.52 | 0.91 | +75.00% | $745.7M | ✅ Beat | -4.62% | -5.54% | -6.42% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $989.7M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 99.5% | $984.4M | +21.1% | $735.6M | $734.6M | $813.0M | $760.8M |
| Royalty And Other | 0.5% | $5.3M | -57.2% | $11.7M | $10.5M | $12.4M | $15.3M |
By region
Q3 FY21 · $408.7M total
| Segment | Share | Revenue | YoY | Q1 FY20 | Q2 FY20 | Q3 FY20 | Q4 FY20 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 48.0% | $196.2M | -22.4% | $244.2M | $232.6M | $252.9M | $182.7M |
| Europe | 28.3% | $115.5M | -4.7% | $145.0M | $109.3M | $121.2M | $143.0M |
| Rest Of World | 14.2% | $58.0M | -1.0% | $52.9M | $49.8M | $58.6M | $62.4M |
| Latin America | 9.5% | $39.0M | -11.6% | $59.9M | $37.9M | $44.1M | $64.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.